Bullous pemphigoid (BP) is chronic pruritic blistering disorder found mainly in aged persons, characterized by the development of tense blisters over an erythematous or urticarial base. IgG antibasement membrane zone antibodies are found in the serum of patients, and linear IgG and C3 sediment is found on the basement membrane zone of the lesion. Several well characterized variants exist including localized, mucous membrane predominant and pemphigoid gestationis, also referred to as herpes gestationis.
Target antigens of the autoantibodies in BP patient serum are BP230 and BP180 also called BPAG1 and BPAG2. Molecular weight of these antigens is 230 kD and 180 kD, respectively. BP180 is thought to be the direct target of the autoantibody because of its location along the basement membranes, and the autoantibody against BP230 is thought to be secondarily produced.
Antibodies to bullous pemphigoid (BP) BP180 and BP230 have been shown to be present in most patients with pemphigoid. Adequate sensitivities and specificity for disease are documented and Mayo's experience demonstrates a very good correlation between BP180 and BP230 results and the presence of pemphigoid (see “Supportive Data"). However, in those patients strongly suspected to have pemphigoid, either by clinical findings or by routine biopsy, and in whom the BP180/BP230 assay is negative, follow-up testing by #8052 “Cutaneous Immunofluorescence Antibodies (IgG), Serum" is recommended.
Antibody titer correlates with disease activity in many patients. Patients with severe disease can usually be expected to have high titers of antibodies to BP. Titers are expected to decrease with clinical improvement.
Synonyms
BP180 AB
BP180 Antibody
BP230 AB
BP230 Antibody
BPAG1 AB
BPAG1 Antibody
BPAG2 AB
BPAG2 Antibody
Sample Type
Serum
Collect
Red top
Amount to Collect
2 mL blood
Preferred Volume
1 mL serum
Minimum Volume
0.5 mL serum
Stability (from collection to initiation)
Room temperature 1.5 days, refrigerated 1 week, frozen 2 weeks
Unacceptable Conditions
Collected in Gold top. Gross hemolysis, lipemia or icterus
Rejection Criteria
Gross hemolysis, lipemia or icterus
Test Code
BPPAB
Sendout
Yes
Performing Lab
Mayo
Specimen Preparation
Spin and freeze aliquot at -20 C. Ship to China basin.
Preferred Volume
1 mL serum
Minimum Volume
0.5 mL serum
Unacceptable Conditions
Collected in Gold top. Gross hemolysis, lipemia or icterus
Rejection Criteria
Gross hemolysis, lipemia or icterus
Stability (from collection to initiation)
Room temperature 1.5 days, refrigerated 1 week, frozen 2 weeks
Units
U
Reference Interval
< 9.0 U
Additional Information
Bullous pemphigoid (BP) is chronic pruritic blistering disorder found mainly in aged persons, characterized by the development of tense blisters over an erythematous or urticarial base. IgG antibasement membrane zone antibodies are found in the serum of patients, and linear IgG and C3 sediment is found on the basement membrane zone of the lesion. Several well characterized variants exist including localized, mucous membrane predominant and pemphigoid gestationis, also referred to as herpes gestationis.
Target antigens of the autoantibodies in BP patient serum are BP230 and BP180 also called BPAG1 and BPAG2. Molecular weight of these antigens is 230 kD and 180 kD, respectively. BP180 is thought to be the direct target of the autoantibody because of its location along the basement membranes, and the autoantibody against BP230 is thought to be secondarily produced.
Antibodies to bullous pemphigoid (BP) BP180 and BP230 have been shown to be present in most patients with pemphigoid. Adequate sensitivities and specificity for disease are documented and Mayo's experience demonstrates a very good correlation between BP180 and BP230 results and the presence of pemphigoid (see “Supportive Data"). However, in those patients strongly suspected to have pemphigoid, either by clinical findings or by routine biopsy, and in whom the BP180/BP230 assay is negative, follow-up testing by #8052 “Cutaneous Immunofluorescence Antibodies (IgG), Serum" is recommended.
Antibody titer correlates with disease activity in many patients. Patients with severe disease can usually be expected to have high titers of antibodies to BP. Titers are expected to decrease with clinical improvement.
CPT Codes
83516-90 x2
Available Stat
No
Test Code
BPPAB
Performing Lab
Mayo
Sendout
Yes
Methodology
ELISA
Collect
Red top
Amount to Collect
2 mL blood
Sample Type
Serum
Preferred Volume
1 mL serum
Minimum Volume
0.5 mL serum
Rejection Criteria
Gross hemolysis, lipemia or icterus
Unacceptable Conditions
Collected in Gold top. Gross hemolysis, lipemia or icterus
Specimen Preparation
Spin and freeze aliquot at -20 C. Ship to China basin.
Units
U
Reference Interval
< 9.0 U
Synonyms
BP180 AB
BP180 Antibody
BP230 AB
BP230 Antibody
BPAG1 AB
BPAG1 Antibody
BPAG2 AB
BPAG2 Antibody
Stability (from collection to initiation)
Room temperature 1.5 days, refrigerated 1 week, frozen 2 weeks
Reported
5-7 days
Additional Information
Bullous pemphigoid (BP) is chronic pruritic blistering disorder found mainly in aged persons, characterized by the development of tense blisters over an erythematous or urticarial base. IgG antibasement membrane zone antibodies are found in the serum of patients, and linear IgG and C3 sediment is found on the basement membrane zone of the lesion. Several well characterized variants exist including localized, mucous membrane predominant and pemphigoid gestationis, also referred to as herpes gestationis.
Target antigens of the autoantibodies in BP patient serum are BP230 and BP180 also called BPAG1 and BPAG2. Molecular weight of these antigens is 230 kD and 180 kD, respectively. BP180 is thought to be the direct target of the autoantibody because of its location along the basement membranes, and the autoantibody against BP230 is thought to be secondarily produced.
Antibodies to bullous pemphigoid (BP) BP180 and BP230 have been shown to be present in most patients with pemphigoid. Adequate sensitivities and specificity for disease are documented and Mayo's experience demonstrates a very good correlation between BP180 and BP230 results and the presence of pemphigoid (see “Supportive Data"). However, in those patients strongly suspected to have pemphigoid, either by clinical findings or by routine biopsy, and in whom the BP180/BP230 assay is negative, follow-up testing by #8052 “Cutaneous Immunofluorescence Antibodies (IgG), Serum" is recommended.
Antibody titer correlates with disease activity in many patients. Patients with severe disease can usually be expected to have high titers of antibodies to BP. Titers are expected to decrease with clinical improvement.
CPT Codes
83516-90 x2
Ordering
Available Stat
No
Performing Lab
Mayo
Methodology
ELISA
Reported
5-7 days
Additional Information
Bullous pemphigoid (BP) is chronic pruritic blistering disorder found mainly in aged persons, characterized by the development of tense blisters over an erythematous or urticarial base. IgG antibasement membrane zone antibodies are found in the serum of patients, and linear IgG and C3 sediment is found on the basement membrane zone of the lesion. Several well characterized variants exist including localized, mucous membrane predominant and pemphigoid gestationis, also referred to as herpes gestationis.
Target antigens of the autoantibodies in BP patient serum are BP230 and BP180 also called BPAG1 and BPAG2. Molecular weight of these antigens is 230 kD and 180 kD, respectively. BP180 is thought to be the direct target of the autoantibody because of its location along the basement membranes, and the autoantibody against BP230 is thought to be secondarily produced.
Antibodies to bullous pemphigoid (BP) BP180 and BP230 have been shown to be present in most patients with pemphigoid. Adequate sensitivities and specificity for disease are documented and Mayo's experience demonstrates a very good correlation between BP180 and BP230 results and the presence of pemphigoid (see “Supportive Data"). However, in those patients strongly suspected to have pemphigoid, either by clinical findings or by routine biopsy, and in whom the BP180/BP230 assay is negative, follow-up testing by #8052 “Cutaneous Immunofluorescence Antibodies (IgG), Serum" is recommended.
Antibody titer correlates with disease activity in many patients. Patients with severe disease can usually be expected to have high titers of antibodies to BP. Titers are expected to decrease with clinical improvement.
Synonyms
BP180 AB
BP180 Antibody
BP230 AB
BP230 Antibody
BPAG1 AB
BPAG1 Antibody
BPAG2 AB
BPAG2 Antibody
Collection
Sample Type
Serum
Collect
Red top
Amount to Collect
2 mL blood
Preferred Volume
1 mL serum
Minimum Volume
0.5 mL serum
Stability (from collection to initiation)
Room temperature 1.5 days, refrigerated 1 week, frozen 2 weeks
Unacceptable Conditions
Collected in Gold top. Gross hemolysis, lipemia or icterus
Rejection Criteria
Gross hemolysis, lipemia or icterus
Processing
Test Code
BPPAB
Sendout
Yes
Performing Lab
Mayo
Specimen Preparation
Spin and freeze aliquot at -20 C. Ship to China basin.
Preferred Volume
1 mL serum
Minimum Volume
0.5 mL serum
Unacceptable Conditions
Collected in Gold top. Gross hemolysis, lipemia or icterus
Rejection Criteria
Gross hemolysis, lipemia or icterus
Stability (from collection to initiation)
Room temperature 1.5 days, refrigerated 1 week, frozen 2 weeks
Result Interpretation
Units
U
Reference Interval
< 9.0 U
Additional Information
Bullous pemphigoid (BP) is chronic pruritic blistering disorder found mainly in aged persons, characterized by the development of tense blisters over an erythematous or urticarial base. IgG antibasement membrane zone antibodies are found in the serum of patients, and linear IgG and C3 sediment is found on the basement membrane zone of the lesion. Several well characterized variants exist including localized, mucous membrane predominant and pemphigoid gestationis, also referred to as herpes gestationis.
Target antigens of the autoantibodies in BP patient serum are BP230 and BP180 also called BPAG1 and BPAG2. Molecular weight of these antigens is 230 kD and 180 kD, respectively. BP180 is thought to be the direct target of the autoantibody because of its location along the basement membranes, and the autoantibody against BP230 is thought to be secondarily produced.
Antibodies to bullous pemphigoid (BP) BP180 and BP230 have been shown to be present in most patients with pemphigoid. Adequate sensitivities and specificity for disease are documented and Mayo's experience demonstrates a very good correlation between BP180 and BP230 results and the presence of pemphigoid (see “Supportive Data"). However, in those patients strongly suspected to have pemphigoid, either by clinical findings or by routine biopsy, and in whom the BP180/BP230 assay is negative, follow-up testing by #8052 “Cutaneous Immunofluorescence Antibodies (IgG), Serum" is recommended.
Antibody titer correlates with disease activity in many patients. Patients with severe disease can usually be expected to have high titers of antibodies to BP. Titers are expected to decrease with clinical improvement.
Administrative
CPT Codes
83516-90 x2
Complete View
Available Stat
No
Test Code
BPPAB
Performing Lab
Mayo
Sendout
Yes
Methodology
ELISA
Collect
Red top
Amount to Collect
2 mL blood
Sample Type
Serum
Preferred Volume
1 mL serum
Minimum Volume
0.5 mL serum
Rejection Criteria
Gross hemolysis, lipemia or icterus
Unacceptable Conditions
Collected in Gold top. Gross hemolysis, lipemia or icterus
Specimen Preparation
Spin and freeze aliquot at -20 C. Ship to China basin.
Units
U
Reference Interval
< 9.0 U
Synonyms
BP180 AB
BP180 Antibody
BP230 AB
BP230 Antibody
BPAG1 AB
BPAG1 Antibody
BPAG2 AB
BPAG2 Antibody
Stability (from collection to initiation)
Room temperature 1.5 days, refrigerated 1 week, frozen 2 weeks
Reported
5-7 days
Additional Information
Bullous pemphigoid (BP) is chronic pruritic blistering disorder found mainly in aged persons, characterized by the development of tense blisters over an erythematous or urticarial base. IgG antibasement membrane zone antibodies are found in the serum of patients, and linear IgG and C3 sediment is found on the basement membrane zone of the lesion. Several well characterized variants exist including localized, mucous membrane predominant and pemphigoid gestationis, also referred to as herpes gestationis.
Target antigens of the autoantibodies in BP patient serum are BP230 and BP180 also called BPAG1 and BPAG2. Molecular weight of these antigens is 230 kD and 180 kD, respectively. BP180 is thought to be the direct target of the autoantibody because of its location along the basement membranes, and the autoantibody against BP230 is thought to be secondarily produced.
Antibodies to bullous pemphigoid (BP) BP180 and BP230 have been shown to be present in most patients with pemphigoid. Adequate sensitivities and specificity for disease are documented and Mayo's experience demonstrates a very good correlation between BP180 and BP230 results and the presence of pemphigoid (see “Supportive Data"). However, in those patients strongly suspected to have pemphigoid, either by clinical findings or by routine biopsy, and in whom the BP180/BP230 assay is negative, follow-up testing by #8052 “Cutaneous Immunofluorescence Antibodies (IgG), Serum" is recommended.
Antibody titer correlates with disease activity in many patients. Patients with severe disease can usually be expected to have high titers of antibodies to BP. Titers are expected to decrease with clinical improvement.
